Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEA CAR-T for Advanced Lung Cancer
NCT06768151Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of C-13-60 in lung cancer (2 arms), sponsored by Chongqing Precision Biotech. Primary endpoint: Safety and Tolerability of CAR T cell preparations at 28 days. Started Dec 2024; status: recruiting.
02
Drugs
C-13-60
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT06768151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06768151.